Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Large Cap
Health Score : 7.91Divis Laboratories exhibits strong financial health, particularly in solvency, growth, and profitability. The company maintains a debt-free status, showcasing financial stability and low risk. Revenue, operating profit, and EPS have shown significant growth, indicating effective management and market positioning. Profitability margins such as ROCE, ROE and ROA are favorable. However, efficiency ratios are relatively low, suggesting potential challenges in asset utilization and inventory management. The company's liquidity position is strong, with high current, quick, and cash ratios, ensuring it can meet its short-term obligations. Overall, Divis Laboratories demonstrates robust financial performance, with opportunities to improve its operational efficiency.
Health Score : 7.91Divis Laboratories exhibits strong financial health, particularly in solvency, growth, and profitability. The company maintains a debt-free status, showcasing financial stability and low risk. Revenue, operating profit, and EPS have shown significant growth, indicating effective management and market positioning. Profitability margins such as ROCE, ROE and ROA are favorable. However, efficiency ratios are relatively low, suggesting potential challenges in asset utilization and inventory management. The company's liquidity position is strong, with high current, quick, and cash ratios, ensuring it can meet its short-term obligations. Overall, Divis Laboratories demonstrates robust financial performance, with opportunities to improve its operational efficiency.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
93.33
Industry Median
30.91
Large Cap Median
32.45
P/E RATIO
94.75
P/B RATIO
14.52
Industry Median
3.69
Large Cap Median
4.94
P/S RATIO
22.57
Industry Median
3.74
Large Cap Median
6.08
Others
PEG RATIO
17.88
EV/EBITDA RATIO
60.65
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹9165 as on Sep 1, 2026.
Growth Score : 10.00The company demonstrates excellent growth across all key metrics. Strong revenue growth indicates increasing market demand and effective sales strategies. High operating profit growth reflects efficient cost management. Robust EPS and net income growth confirm enhanced profitability. Significant asset growth suggests strategic investments and expansion. These consistent high-growth rates position the company favorably for future success.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 28.57 | -13.3 | 0.99 | 19.31 | 12.82 |
| Operating Profit Growth Rate | 35.51 | -39 | -6.75 | 34.52 | 15.74 |
| Earnings Per Share (EPS) Growth | 49.19 | -38.41 | -12.26 | 36.93 | 17.21 |
| Asset Growth Rate | 24.04 | 7.97 | 7.18 | 9.45 | 18.39 |
| Net Income Growth Rate | 49.19 | -38.41 | -12.23 | 36.94 | 17.21 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Divis Laboratories Ltd | 7.91 | 94.75 | Highly Overvalued | 3441.00 | 98.20 | 2568.00 |
| 2 | Lupin Ltd | 7.84 | 18.46 | Neutral | 8816.00 | 139.24 | 5355.00 |
| 3 | Cipla Ltd | 7.62 | 29.63 | Neutral | 5883.00 | 43.51 | 3862.00 |
| 4 | Mankind Pharma Ltd | 7.61 | 50.85 | Overvalued | 3617.00 | 49.34 | 1938.00 |
| 5 | Zydus Lifesciences Ltd | 7.60 | 23.31 | Neutral | 8475.00 | 35.69 | 5124.00 |
| 6 | Dr Reddys Laboratories Ltd | 6.68 | 23.29 | Neutral | 6454.00 | 38.57 | 4158.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Divi's Laboratories is a leading Indian pharmaceutical company specializing in Active Pharmaceutical Ingredients (APIs) and Custom Synthesis for global innovator companies. With strong R&D and manufacturing capabilities, it's a major player in the global pharmaceutical industry, known for quality, cost-efficiency, and a diverse product portfolio.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Divis Laboratories Ltd's P/E ratio (TTM) is 93.33, compared to the industry median of 30.91 and large cap median of 32.45.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Divis Laboratories Ltd's P/B ratio is 14.52, compared to the industry median of 3.69 and large cap median of 4.94.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Divis Laboratories Ltd's P/S ratio is 22.57, compared to the industry median of 3.74 and large cap median of 6.08.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Divis Laboratories Ltd's PEG ratio is 17.88.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Divis Laboratories Ltd's EV/EBITDA ratio is 60.65.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Divis Laboratories Ltd's ROE is 15.32%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Divis Laboratories Ltd's ROA is 17.18%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Divis Laboratories Ltd's ROCE is 22%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Divis Laboratories Ltd's operating margin is 32.59%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Divis Laboratories Ltd's net margin is 24.32%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Divis Laboratories Ltd's current ratio is 3.47.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Divis Laboratories Ltd's debt-to-equity ratio is 0.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Divis Laboratories Ltd's interest coverage ratio is 148.30.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Divis Laboratories Ltd's DPS is ₹29.99.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Divis Laboratories Ltd's EPS is 17.21.
(Source line: "Ratios as of 15 Oct 2026, based on last traded price of ₹9165. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1990
Headquarters: Hyderabad, Telangana
Core Offerings: Active Pharmaceutical Ingredients (APIs), Custom Synthesis, Intermediates, Nutraceutical Ingredients
Stock Listing: NSE (DIVISLAB), BSE (532488)
Promoter: Dr. Murali K. Divi and family
1990: Incorporated by Dr. Murali K. Divi. 1994: Commenced commercial operations. 1997: Commissioned Unit-I at Choutuppal, Telangana. 2002: Commissioned Unit-II at Visakhapatnam, Andhra Pradesh. 2003: Successfully completed Initial Public Offering (IPO) and listed on Indian stock exchanges. Present: Established as one of the world's leading manufacturers of APIs, intermediates, and custom synthesis solutions, serving global pharmaceutical majors.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Active Pharmaceutical Ingredients (APIs) | 51% | Operating Profit |
| Custom Synthesis | 49% | Operating Profit |
Active Pharmaceutical Ingredients (APIs): Manufactures a wide range of generic APIs for various therapeutic areas, serving regulated markets globally. Focus on high-volume, cost-effective production with strong backward integration.
Custom Synthesis: Provides contract research and manufacturing services (CRMO) for innovator pharmaceutical companies, developing and manufacturing proprietary APIs and intermediates under strict confidentiality.
Nutraceutical Ingredients: Produces active ingredients for the health and wellness industry, including carotenoids and other specialized products.
Dr. Murali K. Divi (Chairman & Managing Director): Founder of Divi's Laboratories, he holds a Ph.D. in Pharmaceutical Sciences and brings over four decades of rich experience in the global pharmaceutical industry, leading the company's strategic vision. Dr. Kiran S. Divi (Whole-time Director & CEO): Son of Dr. Murali K. Divi, he is instrumental in driving the company's operational efficiency, business development, and overall growth, with a strong focus on technology and quality.
Divi's Laboratories (USA) Inc.
Divi's Laboratories (Europe) AG
No major recent corporate actions on record.
The Divis Laboratories Ltd share price today is ₹9165 on NSE (DIVISLAB), as of 15 Oct 2026.
As of 15 Oct 2026, Divis Laboratories Ltd share price is ₹9165, with previous close ₹9165. Today's range is ₹9165 to ₹9165. The 52-week range is ₹5647.50 to ₹9740.
As of today, Divis Laboratories Ltd's market cap is ₹2,38,381.65 crore (Large Cap).
Divis Laboratories Ltd's current P/E ratio is 93.33, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 38.
Divis Laboratories Ltd's current P/B ratio is 14.52.
Divis Laboratories Ltd's current dividend yield is 0.33%. Last dividend of ₹30.00 per share was declared on 19-Aug-2024.
Divis Laboratories Ltd's EPS (TTM) is ₹17.21.
Divi's Laboratories is a leading Indian pharmaceutical company specializing in Active Pharmaceutical Ingredients (APIs) and Custom Synthesis for global innovator companies. With strong R&D and manufacturing capabilities, it's a major player in the global pharmaceutical industry, known for quality, cost-efficiency, and a diverse product portfolio.
Divis Laboratories Ltd is promoted by Dr. Murali K. Divi and family, holding 51.88% as of 15 Oct 2026.
Divis Laboratories Ltd is listed on NSE (DIVISLAB) and BSE (532488). Its next quarterly results are expected on October/November 2024 (Q2 FY25).
Equity Dividend Coverage Ratio
Financial Health & Prudence
